COLLEGIO DI DIREZIONE - Azienda Ospedaliera di Parma

were tested by using the Pearson correlation coefficient. Adjusted multiple logistic regression models were applied to
assess the relationships between mCAC, FEV1, MLA, and emphysema extent and all-cause mortality and CVEs.
Results: The final study cohort consisted of 1159 smokers. There were no significant correlations between mCAC score
and FEV1 (r = -0.03, P = .4), MLA (r = -0.01, P = .7), or emphysema extent (r = 0.02, P = .6). An mCAC score greater
than 400 was the only factor that was independently associated with both all-cause mortality (odds ratio [OR]: 3.73;
95% confidence interval [CI]: 1.05, 13.32; P = .04) and CVEs (OR: 2.87; 95% CI: 1.13, 7.27; P = .03). Conclusion:
mCAC is a better predictor of CVE and all-cause mortality than FEV1 and emphysema extent and may contribute to the
identification of high-risk individuals in a lung cancer screening setting.
79) Tagliaferri, A; Di Perna, C; Riccardi, F; Pattacini, C; Rivolta, GF; Franchini, M (2012) The natural
history of mild haemophilia: a 30-year single centre experience HAEMOPHILIA 18(2):166-174 IF=2.364
[Article]
Although up to 50% of all haemophilic patients followed at haemophilia treatment centres (HTCs) are affected by a
mild factor VIII (FVIII) or factor IX (FIX) defect, published data regarding the natural history of these disorders are
scarce. To fill this lack of information, a retrospective single centre study was conducted. All cases with mild
haemophilia (75 A and 7 B) followed at the regional reference HTC of Parma were evaluated. The patients median age
at diagnosis was 11.5 years and their median age at first bleeding was 5.5 years; 95% of patients had a history of
haemorrhagic problems during their life. Twenty-three percent of patients were infected by HCV, and none by HIV.
Genetic analysis was performed in 80 patients (97% haemophilia A and 100% haemophilia B) and 21 different
mutations were characterized. Eleven percent of patients had never received treatment, whereas 67% were treated with
plasma-derived or recombinant FVIII/FIX concentrates (4% developed inhibitors). desmopressin (DDAVP) was used in
80% of the haemophilia A patients. The response to DDAVP was closely related to the patients genetic profile, as 60%
of non-responders had a mutation in the F8 promoter region. Patients with mild haemophilia may experience a variety
of medical problems, sometimes challenging for the physicians, during their lifetime. The HTCs play an important role
in the management of these patients, whose diagnosis is often delayed. The HTCs should improve patients knowledge
and consideration of their disease and encourage them to maintain regular contact with their haemophilia care provider.
80) Tagliaferri, A; Di Perna, C; Santoro, C; Schinco, P; Santoro, R; Rossetti, G; Coppola, A; Morfini, M;
Franchini, M (2012) Cancers in patients with hemophilia: a retrospective study from the Italian Association
of Hemophilia Centers JOURNAL OF THROMBOSIS AND HAEMOSTASIS 10(1):90-95 IF=5.439
[Article]
. Background: The increased life expectancy of the hemophilia population, primarily as a result of advances in factor
replacement therapy, has enabled hemophiliacs to reach an older age. Consequently, age-related diseases, such as
cardiovascular disorders and cancers, are being increasingly recognized in such patients. However, only few data are
available on such co-morbidities, their management and impact on the primary bleeding disorders. Objectives: With the
aim of investigating several still unclear issues regarding cancers in hemophilia patients, we conducted, on behalf the
Italian Association of Hemophilia Centers (AICE), a study on cancers among Italian hemophiliacs. Patients: Data
pertaining to 122 hemophiliacs with 127 cancers between 1980 and 2010 were retrospectively collected in 21 centers of
the AICE which chose to participate. Results: Sixty-nine percent of cancers were recorded during the decade 20012010.